Summary
Dopamine-3-O-sulfate (DA-3-O-S) and dopamine-4-O-sulfate (DA-4-O-S) are important end products of L-dopa metabolism. Therefore they may give indications of disturbances in the peripheral metabolism of catecholamines, when measured in urine samples of patients with Parkinson’s disease (PD). In addition, information about the reliability of DA sulfatation after L-dopa therapy may be of significance for its role in the elimination of DA from the peripheral nervous system.
Although DA-3-O-S appears to be the predominant sulfo-conjugate in urine, there are no changes in PD nor in depression syndrome compared to controls with or without other neurological disorders. By contrast, DA-4-O-S is significantly decreased in de novo PD subjects. However, a similar reduction is notable in patients with other neurological disorders. In depressed persons the loss of this compound was less pronounced as compared to de novo PD. Treatment with combined L-dopa therapy caused increased excretion of DA-3-O-S, while changes in DA-4-O-S were only marginal. It is concluded that urinary DA-3-O-S cannot be used as marker for PD, while DA-4-O-S is significantly reduced in a variety of neurological disorders and in particular in de novo PD. Further studies are necessary to elucidate its role as possible peripheral marker to distinguish preclinical PD and depression syndrome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bacopoulos NG, Hattox SE, Roth RH (1979) 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 56:225–236.
Bailey EV, Stone TW (1975) The mechanism of action of amantadine in parkinsonism — a review. Arch Int Pharmacodyn 216:246–262.
Barbeau A (1969) Parkinson’s disease as a systemic disorder. In: Gillingham FJ, Sonaldson ML (eds) 3rd Symp. on Parkinson’s disease. Livingstone, Edinburg, pp 66-73.
Bronaugh RL, Mattox SE, Hoehn MM, Murphy RC, Rutledge CO (1975) The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of parkinsonian patients. J Pharmacol Exp Ther 195:441–452.
Buu NT (1985) Dopamine sulfoconjugation in the rat brain: regulation by monoamine oxidase. J Neurochem 45(2): 470–476.
Elchisak MA (1987) Analytical techniques for the determination of phenolic amine neurotransmitter conjugates. Life Sci 41(7):913–916.
Hoehn MM and Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology (Minneap) 17:427–442.
Jellinger K (1989) Pathology of Parkinson’s syndrome. In: Calne DB (ed) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg New York Tokyo, pp 47–112.
Jenner NW, Rose FA (1973) Studies on the separation of 3,4-dihydroxy-phenylethylamine (dopamine) and related compounds by rat tissues. Biochem J 135:109–114.
Johnson CA, Baker CA, Smith RT (1980) Radioenzymatic assay of sulphate conjugates of catecholamines and DOPA in plasma. Life Sci 26:1591–1598.
Kienzl E, Eichinger K (1988) Preparation of dopamine 3-O-sulfate and dopamine 4-O-sulfate as reference substances and high performance liquid Chromatographie trace determination. J Chromatogr 430:263–269.
Kienzl E, Eichinger K, Jellinger K, Kuhn W, Fuchs G, Riederer R (1990) Dopamine-sulfate conjugates in Parkinson’s disease. In: New vistas in drug research. Springer, Wien New York (in press).
Lenman JAR, Turnbull MJ, Reid A, Fleming AM (1977) Urinary monoamine metabolite excretion in disorders of movement. J Neurol Sci 32:219–225.
Quick H, Sourkes TL (1977) Central dopaminergic and serotoninergic systems in the regulation of adrenal tyrosine hydroxylase. J Neurochem 28:137–147.
Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic cncephalopathies. J Neural Transm [Suppl] 14:121–131.
Rivett AJ, Eddy BJ, Roth JA (1982) Contribution of sulfate conjugation, deamination and O-methylation to metabolism of dopamine and norepinephrine in human brain. J Neurochem 39:1009–1016.
Rivett AJ, Francis A, Whittemore R, Roth JA (1984) Sulfate conjugation of dopamine in rat brain: regional distribution of activity and evidence for neuronal localisation. J Neurochem 5:1444–1448.
Rutledge CD, Hoehn M (1973) Sulfate conjugation and L-dopa treatment of parkinsonian patients. Nature 244:447–450.
Scott MC, Elchisak MA (1983) Cardiovascular effects of dopamine sulfate in anesthetized dogs. Fed Proc 42:1363.
Sofie E (1986) Thesis, Techn Univ Vienna, Austria.
Van Loon GR, Sole M J, Bain J (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28:425–434.
Van Loon GR (1980) Abnormal catecholamine mechanisms in hypothalamicpituitary disorders. Metabolism 29(11) [Suppl] 1:1198–1202.
Westerink BHC, ten Kate N (1986) 24 h excretion patterns of free, conjugated and methylated catecholamines in man. J Clin Chem Clin Biochem 24:513–519.
Yamamoto T, Yamatodani A, Nishimura AM (1985) Determination of dopamine-3-and-4-O-sulfate in human plasma and urine by anion-exchange high-performance liquid chromatography with fluorimetric detection. J Chromatogr 342:261–267.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag
About this paper
Cite this paper
Kienzl, E. et al. (1990). Urinary dopamine sulfate: regulations and significance in neurological disorders. In: Riederer, P., Youdim, M.B.H. (eds) Amine Oxidases and Their Impact on Neurobiology. Journal of Neural Transmission, vol 32. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9113-2_64
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9113-2_64
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82239-5
Online ISBN: 978-3-7091-9113-2
eBook Packages: Springer Book Archive